McMaster University and Population Health Research Institute, Hamilton, Canada.
Ann Intern Med. 2011 Mar 1;154(5):310-8. doi: 10.7326/0003-4819-154-5-201103010-00005.
Glomerular filtration rate and albuminuria are risk factors for cardiovascular disease and markers of renal function.
To examine the contribution of estimated glomerular filtration rate (eGFR) and urinary albumin-creatinine ratio beyond that of traditional cardiovascular risk factors to classification of patient risk for cardiovascular and renal outcomes.
Prospective cohort study that pooled all patients of ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial) and TRANSCEND (Telmisartan Randomized Assessment Study in Angiotensin-Converting-Enzyme-Inhibitor Intolerant Subjects with Cardiovascular Disease).
27,620 patients older than 55 years with documented cardiovascular disease, who were followed for a mean of 4.6 years.
Baseline eGFR, urinary albumin-creatinine ratio, and cardiovascular risk factors. Outcomes were all-cause mortality; a composite of cardiovascular death, myocardial infarction, stroke, and hospitalization for heart failure; long-term dialysis; and a composite of long-term dialysis and doubling of serum creatinine level.
Lower eGFRs and higher urinary albumin-creatinine ratios were associated with the primary cardiovascular composite outcome (for example, an adjusted hazard ratio of 2.53 [95% CI, 1.61 to 3.99] for an eGFR <30 mL/min per 1.73 m(2) and a very high urinary albumin-creatinine ratio). However, adding information about eGFR and urinary albumin-creatinine ratio to the risk reclassification analyses led to no meaningful decrease in the proportion of patients assigned to the intermediate-risk category (31% without vs. 32% with renal information). In contrast, eGFR and urinary albumin-creatinine ratio were strongly associated with risk for long-term dialysis and greatly improved both model calibration and risk stratification capacity when added to traditional cardiovascular risk factors (65% assigned to intermediate-risk categories without renal information vs. 18% with renal information).
Creatinine levels were not standardized.
In patients with high vascular risk, eGFR and urinary albumin-creatinine ratio add little to traditional cardiovascular risk factors for stratifying cardiovascular risk but greatly improve risk stratification for renal outcomes.
Boehringer Ingelheim, Population Health Research Institute, and the European Commission.
肾小球滤过率和白蛋白尿是心血管疾病的风险因素,也是肾功能的标志物。
研究估算肾小球滤过率(eGFR)和尿白蛋白/肌酐比值对心血管和肾脏结局患者风险分类的贡献,超出传统心血管危险因素的作用。
前瞻性队列研究,将 ONTARGET(替米沙坦单药治疗和与雷米普利联合治疗全球终点试验)和 TRANSCEND(替米沙坦在血管紧张素转换酶抑制剂不耐受的心血管疾病患者中的随机评估研究)的所有患者进行汇总。
27620 名年龄大于 55 岁且有心血管疾病病史的患者,平均随访 4.6 年。
基线 eGFR、尿白蛋白/肌酐比值和心血管危险因素。结局为全因死亡率;心血管死亡、心肌梗死、卒中和心力衰竭住院的复合终点;长期透析;以及长期透析和血清肌酐水平翻倍的复合终点。
较低的 eGFR 和较高的尿白蛋白/肌酐比值与主要心血管复合结局相关(例如,eGFR <30 mL/min/1.73 m2的校正风险比为 2.53[95%CI,1.61 至 3.99],尿白蛋白/肌酐比值非常高)。然而,将 eGFR 和尿白蛋白/肌酐比值的信息加入风险再分类分析中,并没有导致中间风险类别患者的比例有意义地下降(无肾信息时为 31%,有肾信息时为 32%)。相比之下,eGFR 和尿白蛋白/肌酐比值与长期透析风险密切相关,并在加入传统心血管危险因素后极大地改善了模型校准和风险分层能力(无肾信息时 65%分配到中间风险类别,有肾信息时 18%)。
肌酐水平未标准化。
在高血管风险患者中,eGFR 和尿白蛋白/肌酐比值对分层心血管风险的作用很小,但对肾脏结局的风险分层作用很大。
勃林格殷格翰公司、人口健康研究所和欧盟委员会。